DMA4-H228
DC60856
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | Not available |
| Chemical Name | AMG514 |
| Synonyms | AMG-514, AMG 514 |
| SMILES | CCCCCCCCC(CCCCCC)C(=O)OCCCCCCC(O)CN1CCC2(CC1)CCN(CC(O)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)C2 |
| Formula | C56H108N2O6 |
| M.Wt | 905.49 |
| Purity | ELSD>95% |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Gupta A, Das R, Reed K, et al. Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. Nature Biotechnology. Published online 13 May 2026. |
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| AMG514 | 35 | Ionizable lipid |
| DOPE | 16 | Helper phospholipid |
| Cholesterol | 46.5 | Sterol |
| DMG-PEG2k | 2.5 | PEG lipid |
| Reported total | 100 | Source values retained |
Formulation weight calculator
The cited formulation and available component molecular weights are pre-filled. Enter the exact molecular weight for any substituted material before calculating.
The 4 reported lipid components total 100 mol%.
| Component | Molecular weight (g/mol) | Literature molar ratio |
|---|---|---|
| AMG514 | ||
| DOPE | ||
| Cholesterol | ||
| DMG-PEG2k |
Calculated component requirements
| Component | Normalized mol% | Amount (µmol) | Required weight (mg) |
|---|---|---|---|
| Total | 100.000% | — | — |
Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
Literature-reported performance for the cited formulation
Literature-reported97%Post-formulation characterization · Representative cKK-E12 LNP: 56%Supplementary Table 2, internal p. 25 / PDF p. 26
Literature-reported102.7 nmPost-formulation characterization · Representative cKK-E12 LNP: 86.0 nmSupplementary Table 2, internal p. 25 / PDF p. 26
Literature-reported0.133Post-formulation characterization · Representative cKK-E12 LNP: 0.155Supplementary Table 2, internal p. 25 / PDF p. 26
Literature-reportedapproximately 7.5Post-formulation characterization · Approximately 6.5 is described as characteristic of the cited liver-tropic formulationsMain text p. 11; Supplementary Figure 21b
Literature-reportedapproximately four-fold higher6 h after a single 1 microgram IV FLuc-mRNA dose · Versus cKK-E12 LNP; reduced liver signal was also reportedMain text p. 9; Extended Data Figure 4c,d
Additional reported findings
In the Ai14/Cre reporter experiment, the plotted fractions were approximately 67% versus 40% tdTomato-positive dendritic cells and approximately 60% versus 40% tdTomato-positive macrophages for AMG514 versus cKK-E12.
Cre mRNA, IV, n=4-5; the figure caption reports 5 micrograms and 48 h, while Methods report 0.25 mg/kg and 72 h · Extended Data Figure 4e and MethodsAMG514-formulated NIK plus OVA generated approximately 15% OVA-tetramer-positive CD8 T cells after boosting, compared with approximately 6% for the cKK-E12 formulation.
C57BL/6J mice; total 3 micrograms RNA; days 0 and 14; n=5; route not stated for this experiment · Main Figure 6f-h and text p. 11AMG514 NIK plus OVA produced complete rejection in five of five mice, compared with three of five for cKK-E12 NIK plus OVA and one of five for AMG514 OVA alone. The authors state that the AMG514 advantage over cKK-E12 was not statistically significant.
Preclinical prophylactic vaccine and tumor-challenge study · Main Figure 6i,j and text p. 11The reported AMG514 corona was enriched in vitronectin, coagulation proteins and selected apolipoproteins. This association does not by itself prove a receptor-mediated targeting mechanism.
The main text refers to plasma, while the Supplementary Figure 21 caption refers to serum · Main text p. 11 and Supplementary Figure 21Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetGupta A, Das R, Reed K, et al. Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. Nature Biotechnology. Published online 13 May 2026. DOI: 10.1038/s41587-026-03115-2
Structure and analytical identity: Extended Data Figure 4a and Supplementary chemical-characterization section; formulation and preparation: Supplementary Table 1 and Methods; reporter delivery: Extended Data Figure 4; vaccination and tumor-challenge findings: Figure 6; protein corona and apparent pKa: main text and Supplementary Figure 21.
Structure and analytical identity: Extended Data Figure 4a and Supplementary chemical-characterization section; formulation and preparation: Supplementary Table 1 and Methods; reporter delivery: Extended Data Figure 4; vaccination and tumor-challenge findings: Figure 6; protein corona and apparent pKa: main text and Supplementary Figure 21.